220 related articles for article (PubMed ID: 35354694)
1. Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan.
Hiramoto S; Miyashita D; Kimura T; Niwa T; Uchida A; Sano M; Murata M; Nagasawa T; Tsunekawa K; Aoki T; Yoshida A; Kato T; Yanagisawa K; Tokue Y; Murakami M
Tohoku J Exp Med; 2022 May; 257(1):57-64. PubMed ID: 35354694
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
4. Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka.
Hoshida S; Koeda N; Hattori H; Tanaka M; Tanaka I; Fukui H; Fujita J; Sasaki Y; Tamura S
BMC Infect Dis; 2022 Aug; 22(1):709. PubMed ID: 36028796
[TBL] [Abstract][Full Text] [Related]
5. SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021.
Wang RC; Murphy CE; Kornblith AE; Hohenstein NA; Carter CM; Wong AHK; Kurtz T; Kohn MA
Am J Emerg Med; 2022 Apr; 54():81-86. PubMed ID: 35144108
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
[TBL] [Abstract][Full Text] [Related]
7. Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
Mwangi LW; Omuse G; Adam R; Ong'ete G; Matheka C; Mugaine P; Sayed S; Maina D
PLoS One; 2024; 19(4):e0299302. PubMed ID: 38573911
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity.
Kara Z; Akçin R; Demir AN; Dinç HÖ; Kocazeybek B; Yumuk VD
Obes Facts; 2022; 15(5):648-654. PubMed ID: 35921804
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study.
Brlić PK; Pavletić M; Lerga M; Krstanović F; Matešić MP; Miklić K; Malić S; Mikša L; Pajcur M; Peruč D; Schubert M; Bertoglio F; Arapović J; Protić A; Šustić A; Milošević M; Šain LČ; Jonjić S; Lisnić VJ; Brizić I
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146773
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of antibody response after COVID-19 vaccination of healthcare workers.
Uysal EB; Gümüş S; Bektöre B; Bozkurt H; Gözalan A
J Med Virol; 2022 Mar; 94(3):1060-1066. PubMed ID: 34704620
[TBL] [Abstract][Full Text] [Related]
12. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months-A Cross-Sectional Study.
Damerau L; Mühlenbruch G; Evenschor-Ascheid A; Fussen C; Nienhaus A; Terschüren C; Herold R; Harth V
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141696
[TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 IgG antibody after the second and third mRNA vaccinations in staff and residents in a nursing home with a previous COVID-19 outbreak in Niigata, Japan.
Wagatsuma K; Saito R; Yoshioka S; Yamazaki S; Sato R; Iwaya M; Takahashi Y; Chon I; Naito M; Watanabe H
J Infect Chemother; 2024 Feb; 30(2):164-168. PubMed ID: 37739181
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
18. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.
Ahn JY; Lee J; Suh YS; Song YG; Choi YJ; Lee KH; Seo SH; Song M; Oh JW; Kim M; Seo HY; Kwak JE; Youn JW; Woo JW; Shin EC; Sung YC; Park SH; Choi JY
Lancet Microbe; 2022 Mar; 3(3):e173-e183. PubMed ID: 35156068
[TBL] [Abstract][Full Text] [Related]
20. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.
Lumley SF; Wei J; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Peck LJ; Ritter TG; de Toledo Z; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Crook DW; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Walker TM; Jeffery K; Eyre DW;
Clin Infect Dis; 2021 Aug; 73(3):e699-e709. PubMed ID: 33400782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
